A 14‐Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma
Article 2017 en
Authors
ES
Erin K. Sykes
CM
Cassandra E. McDonald
SG
Shila Ghazanfar
Abstract
1 min read
The ten differential proteins identified by SRM have biological significance in cancer progression. The final signature of 14 proteins identified by SRM could be used to identify AJCC stage III melanoma patients likely to have poor outcomes who may benefit from adjuvant systemic therapy.
Swetlana Mactier, Kimberley L. Kaufman, Penghao Wang, Ben Crossett, Gulietta M. Pupo, Philippa Kohnke, John F. Thompson, Richard A Scolyer, Jean Yang, Graham J. Mann, Richard I. Christopherson
Manik Garg, Dominique‐Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran Jönsson, Julia Newton‐Bishop, Christine Parkinson, Mark R. Middleton, D. Timothy Bishop, Sarah McDonald, Nikki Stefanos, John A. Tadross, Ismael A. Vergara, Serigne Lo, Felicity Newell, James S. Wilmott, John F. Thompson, Georgina V. Long, Richard A Scolyer, Pippa Corrie, David J. Adams, Alvis Brāzma, Roy Rabbie
Christoph Krisp, Robert Parker, Dana Pascovici, James S. Wilmott, John F. Thompson, Graham J. Mann, Richard A Scolyer, Nicholas K. Hayward, Mark P. Molloy
Lauren E. Haydu, Richard A Scolyer, Serigne Lo, Michael J. Quinn, Robyn P.M. Saw, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, William H. McCarthy, John F. Thompson
Srikanth S. Manda, Adel T. Aref, Erin K. Sykes, Steven G. Williams, Jennifer M.S. Koh, Erin M. Humphries, Daniel Bucio-Noble, Daniela Lee-Smith, Natasha Lucas, Dylan Xavier, Alexander M. Menzies, Inês Da Silva, Felicity Newell, Rosemary L. Balleine, Peter G. Hains, Graham J. Mann, Philip Robinson, Georgina V. Long, James S. Wilmott, Qing Zhong, Richard A Scolyer, Roger R. Reddel
Discussion(0)
No comments yet. Be the first to comment.